Achievement
PUBLICATIONS
2025
Tsubota M, Sasaki K, Shin E, Okamura Y, Nishimura A, Yamagata A, Nonaka Y, Sekiguchi F, Tomono Y, Nishibori M, Okada T, Toyooka N, Kawabata A.HMGB1 derived from macrophages and enteric glial cells contributes to the butyrate-induced colonic hypersensitivity in mice. Eur J Pharmacol. , 177660, 2025.
Watanabe M, Toyomura T, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.Metolazone and azosemide, clinically utilized diuretics, exhibit inhibitory activity for glyoxalase I. Biotechnol Appl Biochem. , e2760, 2025.
Hatipoglu OF, Nishinaka T, Yaykasli KO, Mori S, Watanabe M, Toyomura T, Nishibori M, Hirohata S, Wake H, Takahashi H.Histidine-rich glycoprotein inhibits TNF-α-induced tube formation in human vascular endothelial cells. Front Pharmacol. , 16: 1561628, 2025.
Takahashi Y, Htwe SS, Wang D, Wake H, Yata M, Tomonobu N, Kinoshita R, Sakaguchi M, Nishibori M.Antithrombin regulates neutrophil activities through the stimulation of C-type lectin family 1A. Blood VTH. , 2(1):100032, 2025.
2024
Hisaoka-Nakashima K, Takeuchi Y, Saito Y, Shimoda T, Nakamura Y, Wang D, Liu K, Nishibori M, Morioka N.Glucocorticoids induce HMGB1 release in primary cultured rat cortical microglia. Neuroscience , 560:56-66, 20024.
Ma S, Nakamura Y, Kochi T, Uemoto S, Hisaoka-Nakashima K, Wang D, Liu K, Wake H, Nishibori M, Morioka N.Perineural treatment with high mobility group box-1 monoclonal antibody prevents initiation of pain-like behaviors in female mice with trigeminal neuropathy. Biol Pharm Bull. , 47(1):221-226, 2024.
Gao S, Wang D, Liu K, Tomono Y, Fu L, Gao Y, Takahashi Y, Yata M, Nishibori M.Anti-HMGB1 mAb therapy reduces epidural hematoma injury. Int J Mol Sci. , 25(11): 5889, 2024.
Watanabe M, Toyomura T, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.Cationic ribosomal proteins can inhibit pro-inflammatory action stimulated by LPS+HMGB1 and are hindered by advanced glycation end products. Biotechnol Appl Biochem. , 71: 264-271, 2024.
2023
Nishinaka T, Omer Faruk H, Wake H, Watanabe M, Toyomura T, Mori S, Nishibori M, Takahashi H.Different modulation of STING/TBK1/IRF3 signaling by advanced glycation end products. Arch Biochem Biophys. , 750:109808, 2023.
Murata H, Phoo MTZ, Ochi T, Tomonobu N, Yamamoto KI, Kinoshita R, Miyazaki I, Nishibori M, Asanuma M, Sakaguchi M.Phosphorylated SARM1 is involved in the pathological process of rotenone-induced neurodegeneration. J Biochem. , 174(6):533-548, 2023.
Kitaoka S, Tomohiro A, Ukeshima S, Liu K, Wake H, Kimura SH, Yamamoto Y, Nishibori M, Furuyashiki T.Repeated social defeat stress induces HMGB1 nuclear export in prefrontal neurons, leading to social avoidance in mice. Cells , 12(13):1789, 2023.
Toyomura T, Watanabe M, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.Glycolaldehyde‑derived advanced glycation end products promote macrophage proliferation via the JAK‑STAT signaling pathway. Mol Biol Rep. , 50(7):5849-5858, 2023.
Goyama T, Fujii Y, Muraoka G, Nakatani T, Ousaka D, Imai Y, Kuwada N, Tsuji T, Shuku T, Uchida HA, Nishibori M, Oozawa S, Kasahara S.Comprehensive hemocompatibility analysis on the application of diamond-like carbon to ePTFE artificial vascular prosthesis. Sci Rep. ,13: 8386, 2023.
Dai SJ, Shao YY, Zheng Y, Sun JY, Li ZS, Shi JY, Yan MQ, Qiu XY, Xu CL, Cho WS, Nishibori M, Yi S, Park SB, Wang Y, Chen Z.Inflachromene attenuates seizure severity in mouse epilepsy models via inhibiting HMGB1 translocation. Acta Pharmacol Sin. , 44(9):1737-1747, 2023.
Qiao H, Morioka Y, Wang D, Liu K, Gao S, Wake H, Ousaka D, Teshigawara K, Mori S, Nishibori M.Protective effects of an anti-4-HNE monoclonal antibody against liver injury and lethality of endotoxemia in mice. Eur J Pharmacol. ,175702, 2023.
Kawanoue N, Kuroda K, Yasuda H, Oiwa M, Suzuki S, Wake H, Hosoi H, Nishibori M, Morimatsu H.Consistently low levels of histidine-rich glycoprotein as a new prognostic biomarker for sepsis: a multicenter prospective observational study. PLOS ONE , 18(3):e0283426, 2023.
Hatipoglu OF, Nishinaka T, Nishibori M, Watanabe M, Toyomura T, Mori S, Yaykasli KO, Wake H, Takahashi H.Histamine promotes angiogenesis through a histamine H1 receptor-PKC-VEGF-mediated pathway in human endothelial cells. J Pharmacol Sci. , 151(4): 177-186, 2023.
Namba T, Yashiro M, Fujii Y, Tsuge M, Liu K, Nishibori M, Tsukahara H.Decreased levels of histidine-rich glycoprotein and increased levels of high-mobility group box 1 are risk factors for refractory Kawasaki disease.
Mod Rheumatol., 33(3): 599-607, 2023.
2022
Gao S, Liu K, Ku W, Wang D, Wake H, Qiao H, Teshigawara K, Nishibori M.Histamine induced high mobility group box-1 release from vascular endothelial cells through H1 receptor. Front Immunol., 13:930683, 2022.
Wang D, Ousaka D, Qiao H, Wang Z, Zhao K, Gao S, Liu K, Teshigawara K, Takada K, Nishibori M.Treatment of marmoset intracerebral hemorrhage with humanized anti-HMGB1 mAb. Cells., 11(19): 2970, 2022.
Nishinaka T, Hatipoglu OF, Wake H, Watanabe M, Toyomura T, Mori S, Nishibori M, Takahashi H.Glycolaldehyde-derived advanced glycation end products suppress STING/TBK1/IRF3 signaling via CD36. Life Sci. , 310:121116, 2022.
Du Y, Xu CL, Yu J, Liu K, Lin SD, Hu TT, Qu FH, Guo F, Lou GD, Nishibori M, Hu WW, Chen Z, Zhang SH.HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain. J Headache Pain, 23(1):102, 2022.
Tomonobu N, Kinoshita R, Wake H, Inoue Y, Ruma IMW, Suzawa K, Gohara Y, Komalasari NLGY, Jiang F, Murata H, Yamamoto K, Sumardika IW, Chen Y, Futami J, Yamauchi A, Kuribayashi F, Kondo E, Toyooka S, Nishibori M, Sakaguchi M.Histidine-rich glycoprotein suppresses the S100A8/A9-mediated organotropic metastasis of melanoma cells. Int J Mol Sci., 23(18): 10300, 2022.
Watanabe M, Toyomura T, Ikegami R, Suwaki Y, Sada M, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.Nordihydroguaiaretic acid inhibits glyoxalase I, and causes the accumulation of methylglyoxal followed by cell-growth inhibition. Mol Biol Rep., 49(11): 10499-10507, 2022.
Ousaka D, Nishibori M.Is hemolysis a novel therapeutic target in COVID-19? Front Immunol., 13: 956671, 2022.
Nishibori M. (Commemorative Review Article for the 14th Ebashi Setsuro Award)Novel aspects of sepsis pathophysiology: NETs, plasma glycoproteins, endotheliopathy and COVID-19. J Pharmacol Sci., 150(1): 9-20, 2022.
Hisaoka-Nakashima K, Ohata K, Yoshimoto N, Tokuda S, Yoshii N, Nakamura Y, Wang D, Liu K, Wake H, Yoshida T, Ago Y, Hashimoto K, Nishibori M, Morioka N.High-mobility group box 1-mediated hippocampal microglial activation induces cognitive impairment in mice with neuropathic pain. Exp Neurol. , 335:114146, 2022.
Kamiya M, Mizoguchi F, Kawahata K, Wang D, Nishibori M, Day J, Louis C, Wicks LP, Kohsaka H, Yasuda S.Targeting necroptosis in muscle fibers ameliorates inflammatory myopathies. Nat Commun ., 13(1): 166, 2022.
Sato F, Nakamura Y, Ma S, Kochi T, Hisaoka-Nakashima K, Wang D, Liu K, Wake H, Nishibori M, Morioka N.Central high mobility group box-1 induces mechanical hypersensitivity with spinal microglial activation in a mouse model of hemi-Parkinson’s disease. Biomed Pharmacother ., 145: 112479, 2022.
Miyamoto T, Domoto R, Sekiguchi F, Kamaguchi R, Nishimura R, Matsuno M, Tsubota M, Fujitani M, Hatanaka S, Koizumi Y, Wang D, Nishibori M, Kawabata A.Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplation treatment: Evidence from clinical and preclinical studies. J Pharmacol Sci ., 148(3): 315-325, 2022.
Domoto R, Sekiguchi F, Kamaguchi R, Iemura M, Yamanishi H, Tsubota M, Wang D, Nishibori M, Kawabata A.Role of neuron-derived ATP in paclitaxel-induced HMGB1 release from macrophages and peripheral neuropathy. J Pharmacol Sci. , 148(1): 156-161, 2022.
Watanabe M, Toyomura T, Wake H, Nishinaka T, Hatipoglu OF, Takahashi H, Nishibori M, Mori S.Identification of ribosomal protein L9 as a novel regulator of proinflammatory damage-associated molecular pattern molecules. Mol Biol Rep. , 49(4): 2831-3838, 2022.
2021
Yamazaki Y, Wake H, Nishinaka T, Hatipoglu OF, Liu K, Watanabe M, Toyomura T, Mori S, Yoshino T, Nishibori M, Takahashi H.Involvement of multiple scavenger receptors in advanced glycation end product-induced vessel tube formation in endothelial cells. Exp Cell Res ., 408(1): 112857, 2021.
Tsubota M, Miyazaki T, Ikeda Y, Hayashi Y, Aokiba Y, Tomita S, Sekiguchi F, Wang D, Nishibori M, Kawabata A.Caspase-dependent HMGB1 release from macrophages participates in peripheral neuropathy caused by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice. Cells , 10(10): 2550, 2021.
Volmari A, Foelsch K, Zierz E, Yan K, Qi M, Bartels K, Kondratowicz S, Boettcher M, Reimers D, Nishibori M, Liu K, Schwabe RF, Lohse AW, Huber S, Mittruecker HW, Huebener P.Leukocyte-derived high-mobility group box 1 governs hepatic immune responses to listeria monocytogenes. Hepatol Commun. , 5(12): 2104-2120, 2021.
Namba T, Tsuge M, Yashiro M, Saito Y, Liu K, Nishibori M, Morishima T, Tsukahara H.Anti-high mobility group box 1 monoclonal antibody suppressed hyper-permeability and cytokine production in human pulmonary endothelial cells infected with influenza A virus. Inflamm Res ., 70(10-12): 1101-1111, 2021.
Masai K, Kuroda K, Isooka N, Kikuoka R, Murakami S, Kamimai S, Wang D, Liu K, Miyazaki I, Nishibori M, Asanuma M.Neuroprotective effects of anti-high mobility group box-1 monoclonal antibody against methamphetamine-induced dopaminergic neurotoxicity. Neurotox Res ., 39(5): 1511-1523, 2021.
Nakata K, Okazaki M, Shimizu D, Suzawa K, Shien K, Miyoshi K, Otani S, Yamamoto H, Sugimoto S, Yamane M, Ousaka D, Ohara T, Matsukawa A, Nishibori M, Toyooka S.Protective effects of anti-HMGB1 monoclonal antibody on lung ischemia reperfusion injury in mice. Biochem Biophys Res Commun ., 573: 164-170, 2021.
Araki K, Kinoshita R, Tomonobu N, Gohara Y, Tomida S, Takahashi Y, Senoo S,Taniguchi A, Itano J, Yamamoto KI, Murata H, Suzawa K, Shien K, Yamamoto H, Okazaki M, Sugimoto S, Ichimura K, Nishibori M, Miyahara N, Toyooka S, Sakaguchi M.The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis. J Mol Med (Berl) . 99(1): 131-145, 2021.
Zhu Y, Uezono N, Yasui T, Nakajo M, Nagai T, Wang D, Nishibori M, Nakashima K.Combinatrial treatment of anti-High Mobility Group Box-1 monoclonal antibody and epothilone B improves functional recovery after spinal cord contusion injury. Neurosci Res .,172: 13-25, 2021.
Zhang Y, Ideguchi H, Yamashiro K, Yamamoto T, Nishibori M, Takashiba S.Malnutrition delayed wound healing after tooth extraction by HMGB1-related prolonged inflammation. Int Immunopharmacol ., 96: 107772, 2021.
Kuroda K, Ishii K, Mihara Y, Kawanoue N, Wake H, Mori S, Yoshida M, Nishibori M, Morimatsu H.Histidine-rich glycoprotein as a prognostic biomarker for sepsis. Sci Rep. ,11: 10223, 2021.
Kochi T, Nakamura Y, Ma S, Hisaoka-Nakashima K, Wang D, Liu K, Wake H, Nishibori M, Irifune M, Morioka N.Pretreatment with High Mobility Group Box-1 Monoclonal Antibody Prevents the Onset of Trigeminal Neuropathy in Mice with a Distal Infraorbital Nerve Chronic Constriction Injury. Molecules , 26(7): 2035, 2021.
Nishibori M, Stonestreet BS.Understanding of COVID-19 pathology: much more attention to plasma proteins. Front Immunol. , 12: 656099, 2021.
Nakamura Y, Fukuta A, Miyashita K, Zhang FF, Wang D, Liu K, Wake H, Hisaoka-Nakashima K, Nishibori M, Morioka N.Perineural high-mobility group box 1 induces mechanical hypersensitivity through activation of spinal microglia: involvement of glutamate-NMDA receptor dependent mechanism in spinal dorsal horn. Biochem Pharmacol. , 186, 114496, 2021.
Kitaura A, NishinakaT, Hamasaki S, Hatipoglu OF, Wake H, Nishibori M, Mori S, Nakao S, Takahashi H.Advanced glycation end-products reduce lipopolysaccharide uptake by macrophages. PLosOne. 16(1): e0245957, 2021.
Takahashi Y, Wake H, Sakaguchi M, Yoshii Y, Teshigawara K, Wang D, Nishibori M.Histidine-rich glycoprotein stimulates human neutrophil phagocytosis and prolonged survival through CLEC1A. J Immunol. , ji2000817, 2021.
Hatayama K, Chen RH, Hanson J, Teshigawara K, Qui J, Santoso A, Disdier C, Nakada S, Chen X, Nishibori M, Lim YP, Stonestreet BS.High Mobility Group Box-1 and Inter-alpha Inhibitor Proteins: In vitro binding and co-localization in cerebral cortex after hypoxic-ischemic injury. FASEB J. , 35(3): e21399, 2021.
PATENT
INHIBITOR OF CEREBRAL INFARCTION CEREBRAL VASOSPASM INHIBITOR THERAPEUTIC AGENT FOR TRAUMATIC NEUROLOGICAL DISORDERS THERAPEUTIC AGENT, TREATMENT METHOD AND TEST METHOD FOR DISEASES ASSOCIATED WITH ACTIVATION OF NEUTROPHILS THERAPEUTIC AGENT, METHOD OF TREATMENT AND METHOD FOR PREDICTING THE SEVERITY OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME(SIRS), DISEASES CAUSED OR ACCOMPANIED BY NEUTROPHIL ACTIVATION HUMANIZED ANTI-HMGB1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF USE OF ANTIBODY-DRUG CONJUGATES AND ANTIBODIES FOR DRUG DELIVERY PROTECTIVE AGENT FOR RED BLOOD CELL NOVEL MONOCLONAL ANTIBODY HAVING ANTI-INFLAMMATORY ACTION AGENT FOR ENHANCING PHAGOCYTOSIS ABILITY OF NEUTROPHILS
PAGE TOP
Copyright © Department of Translational Research & Drug Development Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences All Rights Reserved.
